Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Visit https://www.peervoice.com/ZXH860 to view the entire programme with slides. After completing “Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed”, participants will be able to: Apply evidence-based and guideline-recommended best practices for molecular testing and identification of disease progression to guide treatment planning and sequencing for refractory metastatic colorectal cancer (mCRC); Evaluate efficacy and safety data for recommended treatments for mCRC that have progressed through prior treatments; and Identify patient-, disease-, and therapy-specific considerations that influence choice of therapy in patients with refractory mCRC.